
MiMedx Group (MDXG) Stock Forecast & Price Target
MiMedx Group (MDXG) Analyst Ratings
Bulls say
MiMedx Group is a pioneering leader in the development and marketing of regenerative biomaterial products derived from human amniotic tissue, birth tissue, and human skin and bone. Despite headwinds caused by changes in Medicare wound reimbursement and confusion in the industry, MiMedx remains well-positioned for long-term success, with potential for double-digit revenue growth due to its strong product portfolio, ongoing research and development efforts, and expanding presence in the wound care and surgical markets. However, there are potential risks related to tissue donorship, the competitive nature of 361 regulated products, and contracts with group purchasing organizations and integrated delivery networks that could impact the company's future business.
Bears say
MiMedx Group is facing challenges in the form of reimbursement disruptions and a slow recovery in its Wound Care segment, which make it difficult to predict future revenue growth. While the company is making efforts to reduce costs and capitalize on growth opportunities, the stock may continue to underperform in the near term due to these challenges. Additionally, the uncertainty surrounding the impact of the Medicare outpatient ASP caps could further hamper the company's revenue growth in the coming years.
This aggregate rating is based on analysts' research of MiMedx Group and is not a guaranteed prediction by Public.com or investment advice.
MiMedx Group (MDXG) Analyst Forecast & Price Prediction
Start investing in MiMedx Group (MDXG)
Order type
Buy in
Order amount
Est. shares
0 shares